secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sight Sciences, Inc. (SGHT)
CIK:        0001531177
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017868
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sight Sciences Q1 revenue up 26% to $18.8M, net loss $17.1M; reaffirms FY2023 guidance
--------------------------------------------------------------------------------

- Revenue $18.8M (+26% YoY); Surgical Glaucoma $17.3M (+25%), Dry Eye $1.5M (+47%).
- Net loss $17.1M ($0.35/share) vs $23.3M ($0.49) prior year; operating expenses decreased 2% to $33.3M.
- Gross margin improved to 84% from 80% due to prior year voluntary TearCare SmartHub replacement.
- Reaffirmed FY2023 revenue guidance $89-94M (25-32% growth) and ~$30.5M quarterly adjusted opex.
- Completed commercial launch of Ergo-Series OMNI Surgical System; cash $167.3M, debt $35.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023017868/0000950170-23-017868-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531177/000095017023017868/sght-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017868

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer